← 홈

ADC · 난소암

107개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 107개
ADCBiologicstaleEli Lilly and CompanyPhase 1

LY4170156 (LY4170156)

Ovarian Neoplasms; Endometrial Neoplasms · Ovarian Neoplasms

#OvarianNeoplasms#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 2상태 RECRUITING
ADCBiologicstaleMenarini GroupPhase 1

MEN1309 (MEN1309)

Metastatic Solid Tumors; Relapsed/Refractory Non-Hodgkin Lymphoma · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+4
임상시험 2상태 DISCONTINUED
ADCBiologicstaleEli Lilly and CompanyPhase 3

Sofetabart Mipitecan (Sofetabart Mipitecan)

Ovarian Neoplasms; Fallopian Tube Neoplasms · Ovarian Neoplasms

#OvarianNeoplasms#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 2상태 RECRUITING
ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Abemaciclib, dexamethasone, ixazomib, pomalidomide (Abemaciclib, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleByondis B.V.Phase 1

BYON4413 (BYON4413)

Relapsed / Refractory AML; Relapsed / Refractory MDS · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING
ADCBiologicstaleSeagenPreclinical

Brentuximab-Vedotin associated with Bendamustine (Brentuximab-Vedotin associated with Bendamustine)

Relapsed or Refractory Hodgkin Lymphoma · FRα

#FR#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleOnCusp Therapeutics, Inc.Phase 1

CUSP06 (CUSP06)

Ovarian Cancer; Solid Tumor · Ovarian Cancer

#OvarianCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Cobimetinib, dexamethasone, ixazomib, pomalidomide (Cobimetinib, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleGenmabPhase 2

HuMax-AXL-ADC (Enapotamab vedotin, Enapotamab vedotin (HuMax-AXL-ADC))

Ovarian Cancer; Cervical Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 0%임상시험 1상태 ACTIVE
ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Enasidenib, dexamethasone, ixazomib, pomalidomide (Enasidenib, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Erdafitinib, dexamethasone, ixazomib, pomalidomide (Erdafitinib, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleSeagen, a wholly owned subsidia…Phase 1

Felmetatug Vedotin (Felmetatug Vedotin)

Ovarian Neoplasms; Peritoneal Neoplasms · HER2

#HER2#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 DISCONTINUED
ADCBiologicstaleNational Cancer Institute (NCI)Phase 2

Fexagratinib (Fexagratinib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING
ADCBiologicstaleNovartis PharmaceuticalsPhase 1

HKT288 (HKT288)

Epithelial Ovarian Cancer; Renal Cell Carcinoma · Epithelial Ovarian Cancer

#EpithelialOvarianCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 DISCONTINUED
ADCBiologicstaleWhitehawk Therapeutics, Inc.Phase 1

HWK-007 (HWK-007)

Endometrial Cancer; Ovarian Cancer · EGFR

#EGFR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING
ADCBiologicstaleWhitehawk Therapeutics, Inc.Phase 1

HWK-016, MUCIN-16-targeted ADC (HWK-016, MUCIN-16-targeted ADC)

PROC; Platinum Resistant Ovarian Cancer · PROC

#PROC#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleNextCure, Inc.Phase 1

LNCB74 (LNCB74)

Ovarian Cancer; Breast Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleShanghai Miracogen Inc.Phase 1

MRG001 (MRG001)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleAbbViePhase 1

Mirvetuximab + SL-172154 (Mirvetuximab + SL-172154)

Platinum-resistant Ovarian Cancer; Fallopian Tube Cancer · Platinum-resistant Ovarian Cancer

#Platinum-resistantOvarianCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleShattuck Labs, Inc.Phase 1

Pegylated Liposomal Doxorubicin + SL-172154 (Pegylated Liposomal Doxorubicin + SL-172154)

Platinum-resistant Ovarian Cancer; Fallopian Tube Cancer · Platinum-resistant Ovarian Cancer

#Platinum-resistantOvarianCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE

5 / 6 페이지

← 이전다음 →